with the objective of evaluating shortened therapeutic outlines effective in vivax malaria treatment, we accomplished an open, prospective study allocating 234 patients with vivax malaria distributed at random into eight therapeutic groups. Six groups used oral arthemisin as blood esquizonticide at different doses for one day and the other two groups received chloroquine in a single dose. The primaquine was used as a hypnozoiticide in all groups. They received a daily dose of 30mg in the course of five or seven days in all groups. The clearance of parasitaemia in patients treated with arthemisin (independent of dosage) was faster than the chloroquine group (p <0.01). Cure was acheived in 92.3% and 80.2%, in patients treated with primaquine for seven or five days, respectively (p=0.0372).
Vivax malaria; Treatment; Chloroquine; Arthemisin; Primaquine
